Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
Recruiting · NCT06529250 · Registry updated 2026-08-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Intermediate-dose HAD Regimen for CEBPA Double-mutated AML | acute myeloid leukemia | Recruiting | Not applicable | 2026-08-10 | NCT06529250 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 285 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Blood Hospital | Tianjin | China | 2 |